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Blood pressure and incidence of twelve cardiovascular 
diseases: lifetime risks, healthy life-years lost, and 
age-speciﬁ c associations in 1·25 million people
Eleni Rapsomaniki, Adam Timmis, Julie George, Mar Pujades-Rodriguez, Anoop D Shah, Spiros Denaxas, Ian R White, Mark J Caulﬁ eld, 
John E Deanﬁ eld, Liam Smeeth, Bryan Williams, Aroon Hingorani, Harry Hemingway
Summary
Background The associations of blood pressure with the diﬀ erent manifestations of incident cardiovascular disease 
in a contemporary population have not been compared. In this study, we aimed to analyse the associations of blood 
pressure with 12 diﬀ erent presentations of cardiovascular disease. 
Methods We used linked electronic health records from 1997 to 2010 in the CALIBER (CArdiovascular research using 
LInked Bespoke studies and Electronic health Records) programme to assemble a cohort of 1·25 million patients, 
30 years of age or older and initially free from cardiovascular disease, a ﬁ fth of whom received blood pressure-lowering 
treatments. We studied the heterogeneity in the age-speciﬁ c associations of clinically measured blood pressure with 
12 acute and chronic cardiovascular diseases, and estimated the lifetime risks (up to 95 years of age) and cardiovascular 
disease-free life-years lost adjusted for other risk factors at index ages 30, 60, and 80 years. This study is registered at 
ClinicalTrials.gov, number NCT01164371.
Findings During 5·2 years median follow-up, we recorded 83 098 initial cardiovascular disease presentations. In each 
age group, the lowest risk for cardiovascular disease was in people with systolic blood pressure of 90–114 mm Hg and 
diastolic blood pressure of 60–74 mm Hg, with no evidence of a J-shaped increased risk at lower blood pressures. The 
eﬀ ect of high blood pressure varied by cardiovascular disease endpoint, from strongly positive to no eﬀ ect. Associations 
with high systolic blood pressure were strongest for intracerebral haemorrhage (hazard ratio 1·44 [95% CI 1·32–1·58]), 
subarachnoid haemorrhage (1·43 [1·25–1·63]), and stable angina (1·41 [1·36–1·46]), and weakest for abdominal 
aortic aneurysm (1·08 [1·00–1·17]). Compared with diastolic blood pressure, raised systolic blood pressure had a 
greater eﬀ ect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressure 
had a greater eﬀ ect on abdominal aortic aneurysm than did raised systolic pressure. Pulse pressure associations were 
inverse for abdominal aortic aneurysm (HR per 10 mm Hg 0·91 [95% CI 0·86–0·98]) and strongest for peripheral 
arterial disease (1·23 [1·20–1·27]). People with hypertension (blood pressure ≥140/90 mm Hg or those receiving 
blood pressure-lowering drugs) had a lifetime risk of overall cardiovascular disease at 30 years of age of 63·3% (95% 
CI 62·9–63·8) compared with 46·1% (45·5–46·8) for those with normal blood pressure, and developed cardiovascular 
disease 5·0 years earlier (95% CI 4·8–5·2). Stable and unstable angina accounted for most (43%) of the cardiovascular 
disease-free years of life lost associated with hypertension from index age 30 years, whereas heart failure and stable 
angina accounted for the largest proportion (19% each) of years of life lost from index age 80 years.
Interpretation The widely held assumptions that blood pressure has strong associations with the occurrence of all 
cardiovascular diseases across a wide age range, and that diastolic and systolic associations are concordant, are not 
supported by the ﬁ ndings of this high-resolution study. Despite modern treatments, the lifetime burden of 
hypertension is substantial. These ﬁ ndings emphasise the need for new blood pressure-lowering strategies, and will 
help to inform the design of randomised trials to assess them.
Funding Medical Research Council, National Institute for Health Research, and Wellcome Trust.
Copyright © Rapsomaniki et al. Open Access article distributed under the terms of CC BY.
Introduction
High blood pressure was the leading risk factor for the 
overall global burden of disease in 2010.1 The recent 
decrease in cardiovascular mortality in high-income 
countries has been associated with a rise in the numbers 
of patients living with cardiovascular disease, and the 
wider use of preventive drugs. Thus, an up-to-date 
understanding of the associations of blood pressure with 
diﬀ erent non-fatal and fatal cardiovascular disease 
outcomes would help to reﬁ ne strategies for primary 
prevention and inform the design of future clinical trials.
The Prospective Studies Collaboration meta-analysis 
of 61 cohorts recruited between 1950 and 1990 reported 
log-linear associations of systolic and diastolic blood 
pressure with death from ischaemic heart disease and 
stroke, with no apparent threshold below which no 
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further reduction in risk is observed, down to a blood 
pressure of 115/75 mm Hg, in participants aged 
40–89 years.2 These ﬁ ndings predated several public 
health initiatives, including eﬀ orts to reduce salt 
consumption and tobacco use, and the more widespread 
use of blood pressure-lowering treatments for primary 
prevention, and did not provide information about 
major chronic and non-fatal diseases, including heart 
failure, peripheral arterial disease, abdominal aortic 
aneurysm, and stable angina. Importantly, no current 
estimates are available for the lifetime incidence and 
years of life lost associated with hypertension 
attributable to speciﬁ c cardiovascular diseases. 
Although in previous studies investigators have 
estimated the associations of cardiovascular disease 
risk factors with lifetime risks3 or cardiovascular 
disease-free years of life lost,4 their focus was on total 
cardiovascular disease, with only one study so far to 
have analysed the incidence of speciﬁ c cardiovascular 
diseases in a competing risks context.5
We sought to address these limitations in a large 
contemporary cohort, based on linked electronic 
health records, with high prevalent use of blood pressure-
lowering treatments, and with blood pressure 
measurements done as part of usual clinical practice.
Methods
Data sources  
We selected anonymised patients from the CALIBER 
(CArdiovascular research using LInked Bespoke studies 
and Electronic health Records) programme.6 This 
programme was established to provide access to 
longitudinal data of linked electronic health records 
through the creation of a common data model with 
reproducible phenotypes and metadata. Diagnosis codes 
and endpoints in CALIBER have been validated by 
independent groups.7 Patients were linked across four 
clinical data sources: the Clinical Practice Research 
Datalink (CPRD), the Myocardial Ischaemia National 
Audit Project (MINAP) registry, Hospital Episodes 
Statistics (HES), and cause-speciﬁ c mortality. CPRD 
provides information about anthropometric measure-
ments, laboratory tests, clinical diagnoses, prescriptions, 
and medical procedures, coded with the Read clinical 
coding scheme. The primary care practices in CPRD and 
the subset of linked practices used in the present analysis 
are representative of the UK primary care setting8,9 and 
have been validated for epidemiological research.7 
MINAP is a national registry of patients admitted to 
hospital with acute coronary syndromes. HES provides 
information about diagnoses (coded with the tenth 
revision of the International Classiﬁ cation of Diseases 
[ICD-10]) and medical procedures related to all elective 
and emergency hospital admissions across all National 
Health Service hospitals in England.
Study population  
We selected patients from 225 primary care practices 
registered between January, 1997, and March, 2010, who 
were aged 30 years or older at study entry (the index 
date), who had been registered with their practices for at 
least 1 year before the index date and had no previous 
diagnosis of cardiovascular disease. Appendix p 9 shows 
the study ﬂ ow diagram. 
Exposure and baseline risk factors  
Baseline blood pressure and other cardiovascular disease 
risk factors were recorded during consultations in primary 
care. Baseline blood pressure was based on readings taken 
within 2 years of the index date; these readings were 
averaged across repeat measurements when available. In 
sensitivity analyses, we used the blood pressure 
measurement recorded closest to the index date. Patients 
were classiﬁ ed as having hypertension if their baseline 
blood pressure was 140/90 mm Hg or higher, or they had 
Figure 1: Forest plot of HRs (95% CIs) per 20/10 mm Hg increase in systolic (black) or diastolic (grey) blood 
pressure, adjusted for age and sex
 The vertical dashed lines correspond to the associations of SBP (black) or DBP (grey) with total cardiovascular 
disease. Adjustments include age, quadratic age, and stratiﬁ cation by sex and primary care practice. CIs are 
Bonferroni corrected (13 endpoints × 2 variables=26 tests). HR=hazard ratio. SBP=systolic blood pressure. 
DBP=diastolic blood pressure.
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a recorded diagnosis of hypertension, or they received 
repeat prescriptions (at least two monthly packs) for blood 
pressure-lowering drugs (including thiazide diuretics, 
β  blockers, angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, or calcium channel 
blockers). We distinguished isolated systolic hypertension 
in which systolic blood pressure is 140 mm Hg or above 
but diastolic blood pressure is lower than 90 mm Hg, and 
isolated diastolic hypertension in which systolic blood 
pressure is lower than 140 mm Hg but diastolic blood 
pressure is 90 mm Hg or higher. For covariate 
adjustments, we used the most recent measurement 
recorded in the year before the index date. We imputed 
missing covariate values using multiple imputation,10 as 
implemented in the “mice” algorithm in the statistical 
package R. We checked whether the imputations were 
plausible by comparing plots of the distribution of 
recorded and imputed values of all variables. In the 
primary analysis, we excluded patients with no baseline 
blood pressure measurements; in sensitivity analyses we 
included these patients by imputing their blood pressure 
at baseline (details in appendix). Phenotyping algorithms 
combining Read, ICD-10, drug and procedure codes to 
deﬁ ne risk factors and endpoints are available online. 
Endpoints  
Endpoints, as previously deﬁ ned (see appendix pp 1–4),6 
were the initial presentation of cardiovascular disease as 
Figure 2: Forest plots of HRs (95% CIs) for 20/10 mm Hg changes in blood pressure in diﬀ erent age groups, adjusted for age and sex
Models included continuous age, age group, interaction between blood pressure and age group (which is the association reported in the forest plot), and stratiﬁ cation 
by sex and primary care practice. CIs are Bonferroni corrected (3 age groups × 12 endpoints=36 tests). HR=hazard ratio.
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 1·06
 1·14
 1·35
 1·65
 1·17
 0·93
 0·82
 0·75
 0·79
 0·90
 0·96
 1·02
 1·06
 1·12
 1·23
 1·36
 1·01
 1·00
 1·00
 1·04
 1·22
 1·48
 0·71
 1·16
 1·56
 1·94
 1·84
 1·56
 0·94
 1·03
 1·09
 1·19
 1·40
 1·67
 0·85
 1·07
 1·23
 1·43
 1·67
 1·93
 0·88
 1·05
 1·17
 1·27
 1·25
 1·19
(0·47–0·87)
(1·06–1·39)
(1·20–2·67)
(1·41–4·75)
(1·80–6·06)
(2·12–7·04)
(0·70–1·13)
(0·95–1·17)
(0·86–1·58)
(0·82–2·06)
(0·93–2·34)
(1·02–2·71)
(0·70–1·05)
(0·98–1·17)
(0·94–1·59)
(0·97–2·14)
(1·20–2·66)
(1·48–3·32)
(1·02–1·51)
(0·84–0·99)
(0·59–0·97)
(0·46–0·97)
(0·50–1·04)
(0·55–1·29)
(0·86–1·08)
(0·97–1·07)
(0·92–1·22)
(0·92–1·41)
(1·09–1·67)
(1·31–2·07)
(0·70–1·97)
(0·75–1·17)
(0·42–1·59)
(0·28–2·01)
(0·30–2·13)
(0·30–2·73)
(0·82–1·11)
(0·95–1·09)
(0·87–1·29)
(0·84–1·50)
(0·92–1·65)
(0·99–1·87)
(0·81–1·25)
(0·91–1·09)
(0·76–1·31)
(0·69–1·56)
(0·81–1·84)
(0·96–2·28)
(0·22–2·29)
(0·70–1·92)
(0·35–7·01)
(0·20–18·35)
(0·20–17·08)
(0·15–16·29)
(0·64–1·37)
(0·88–1·21)
(0·67–1·76)
(0·58–2·43)
(0·68–2·88)
(0·78–3·55)
(0·68–1·07)
(0·97–1·18)
(0·92–1·63)
(0·93–2·19)
(1·09–2·56)
(1·24–3·01)
(0·62–1·26)
(0·91–1·23)
(0·74–1·85)
(0·65–2·49)
(0·64–2·44)
(0·57–2·48)
31 542
HR
(n=5688)
(n=6110)
(n=5316)
(n=1940)
(n=5798)
(n=1261)
(n=4874)
(n=2452)
(n=254)
(n=879)
(n=4697)
(n=1567)
(n=712)
(n=817)
(n=1227)
(n=860)
(n=3394)
(n=140)
(n=1799)
(n=940)
(n=43)
(n=326)
(n=1022)
(n=384)
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any of 12 cardiovascular diseases diagnosed in primary 
care, secondary care, or at death, and total cardiovascular 
disease (all 12 cardiovascular diseases combined). In 
analyses of lifetime risks and years of life lost, we 
combined ischaemic stroke with unclassiﬁ ed stroke 
because previous studies have shown that 87% of 
unclassiﬁ ed strokes were ischaemic.11 In sensitivity 
analyses, we estimated associations with hospital 
admissions and deaths, or with deaths only. Patients 
were censored on the date of ﬁ rst cardiovascular disease 
presentation, death from other causes, deregistration 
from the practice, or ﬁ nal practice data collection, 
whichever occurred ﬁ rst.
Study approval was granted by the Independent 
Scientiﬁ c Advisory Committee of the Medicines and 
Healthcare products Regulatory Agency and the MINAP 
Academic Group. This study is registered at 
ClinicalTrials.gov, number NCT01164371.
Statistical analysis  
Hazard ratios (HRs) were based on disease-speciﬁ c Cox 
models with time since study entry as the timescale, 
adjusted for baseline age (linear and quadratic term) and 
stratiﬁ ed by sex and primary care practice. We assessed 
between-practice heterogeneity of these associations by 
estimating practice-speciﬁ c associations of blood 
pressure with each outcome and combining them in a 
random-eﬀ ects meta-analysis; this approach allowed us 
to estimate a heterogeneity-adjusted conﬁ dence interval 
and a prediction interval that expresses uncertainty 
about the association in a randomly chosen practice.12 
We veriﬁ ed the proportional hazards assumption by 
plotting the Schoenﬁ eld residuals. We analysed non-
linear associations with blood pressure by modelling 
blood pressure as a continuous variable (rather than as 
blood pressure categories) for which we used restricted 
cubic splines with three knots; this method allows 
estimation of the HRs in comparison to any single 
reference value (we chose 115 mm Hg for systolic blood 
pressure and 75 mm Hg for diastolic blood pressure, 
since these values are close to the mean for each blood 
pressure variable).13 We constructed conﬁ dence intervals 
for HRs, setting the α level (probability of type I error) to 
0·05 and adjusted for the total number of associations 
reported in each set of analyses based on the Bonferroni 
correction. We estimated lifetime risks of each 
cardiovascular disease and years of life lost associated 
with hypertension adjusted for the competing risk of 
other cardiovascular diseases and non-cardiovascular 
disease mortality based on Cox models with age as the 
timescale (details in appendix).14,15 To estimate years of 
life lost attributable to diﬀ erent types of hypertension 
(isolated systolic, isolated diastolic, or other) in a 
particular age group, we ﬁ rst estimated the years of life 
lost for each type of hypertension and computed their 
weighted average, with weights corresponding to their 
relative prevalence in people with hypertension in that 
age group. We estimated conﬁ dence intervals for lifetime 
risks and years of life lost by running the cause-speciﬁ c 
Cox models in 200 bootstrap samples. All analyses were 
done in R version 15.2.
Primary and secondary analyses  
In the primary analysis, we report the associations of 
each outcome with 20/10 mm Hg increase in 
systolic/diastolic blood pressure across all ages, by age 
group (30–59, 60–79, and ≥80 years), and for diﬀ erent 
blood pressure values in each age group, allowing for 
non-linearity in blood pressure associations, and estimate 
the lifetime risks and years of life lost associated with 
hypertension for diﬀ erent index ages (30, 60, and 
80 years). In our secondary analysis, we assess the 
associations of blood pressure with diﬀ erent outcomes 
after further adjustment for smoking status, diabetes, 
total cholesterol, and high-density lipoprotein cholesterol; 
then additional adjustment for body-mass index (BMI); 
and ﬁ nally further adjustment for baseline treatment 
with blood pressure-lowering drugs. Moreover, we study 
the age-adjusted and sex-adjusted associations of 
diﬀ erent cardiovascular outcomes with pulse pressure 
(calculated as systolic blood pressure minus diastolic 
blood pressure), mean arterial pressure (diastolic blood 
pressure plus a third of pulse pressure), and mid-blood 
pressure (0·5 × systolic blood pressure plus 0·5 × diastolic 
blood pressure). We also report sex-speciﬁ c blood 
pressure associations, lifetime risks, and years of life 
lost, and age-adjusted and sex-adjusted blood pressure 
associations by whether or not blood pressure-lowering 
drugs were being used at baseline.
Role of the funding source  
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing 
of the report. The corresponding author had full access 
to all the data in the study and all authors had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The summary characteristics of the patient cohort by 
hypertension status are shown in appendix p 5. Patients 
with missing baseline blood pressure values were 
younger, healthier, more likely to be male, more likely to 
be white, and were less likely to be receiving blood 
pressure-lowering drugs than were patients whose 
baseline blood pressure was recorded (appendix p 6). 
After we excluded the 679 354 patients whose baseline 
blood pressure was missing (35% of the 1 937 360 patients 
Figure 3: Forest plots of HRs (95% CIs) for diﬀ erent cutoﬀ s of systolic blood 
pressure (vs reference 115 mm Hg) adjusted for age and sex
Blood pressure was modelled as a continuous variable with splines with three 
knots. Adjustments include age, quadratic age, and stratiﬁ cation by sex 
and primary care practice. CIs are Bonferroni corrected (3 age 
groups × 6 categories × 12 endpoints=216 tests). HR=hazard ratio.
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HR (95% CI)Age 30–59 years HR (95% CI)Age 60–79 years HR (95% CI)Age ≥80 years
Stable angina (n=3949)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Unstable angina (n=2146)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Myocardial infarction (n=4486)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Unheralded coronary heart disease death (n=861)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Heart failure (n=1245)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Cardiac arrest/sudden cardiac death (n=954)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Transient ischaemic attack (n=2094)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Ischaemic stroke (n=937)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Subarachnoid haemorrhage (n=533)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Intracerebral haemorrhage (n=434)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Peripheral arterial disease (n=2695)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
Abdominal aortic aneurysm (n=310)
 60–74 mm Hg
 75–84 mm Hg
 85–89 mm Hg
 90–94 mm Hg
 95–99 mm Hg
 ≥100 mm Hg
 0·70
 1·15
 1·55
 1·88
 2·30
 3·09
 0·78
 1·10
 1·35
 1·54
 1·76
 2·14
 0·76
 1·11
 1·35
 1·54
 1·75
 2·12
 0·90
 1·08
 1·42
 1·76
 2·18
 3·01
 0·81
 1·14
 1·69
 2·28
 3·09
 4·87
 0·93
 1·06
 1·29
 1·50
 1·74
 2·20
 0·90
 1·06
 1·27
 1·45
 1·67
 2·04
 0·83
 1·11
 1·49
 1·85
 2·30
 3·20
 0·82
 1·12
 1·59
 2·07
 2·70
 4·01
 1·14
 1·08
 1·74
 2·66
 4·06
 7·69
 0·92
 1·04
 1·15
 1·23
 1·32
 1·46
 1·01
 1·06
 1·42
 1·82
 2·34
 3·40
(0·60–0·82)
(1·11–1·19)
(1·45–1·65)
(1·72–2·07)
(2·02–2·61)
(2·57–3·72)
(0·65–0·93)
(1·06–1·14)
(1·24–1·47)
(1·35–1·76)
(1·45–2·12)
(1·63–2·82)
(0·67–0·87)
(1·07–1·14)
(1·27–1·44)
(1·41–1·68)
(1·54–1·98)
(1·76–2·55)
(0·68–1·20)
(1·02–1·16)
(1·25–1·62)
(1·46–2·13)
(1·68–2·84)
(2·05–4·42)
(0·63–1·06)
(1·07–1·21)
(1·51–1·88)
(1·96–2·65)
(2·52–3·78)
(3·63–6·52)
(0·72–1·19)
(1·00–1·12)
(1·13–1·46)
(1·23–1·82)
(1·32–2·31)
(1·46–3·30)
(0·76–1·07)
(1·02–1·10)
(1·17–1·38)
(1·27–1·66)
(1·37–2·02)
(1·54–2·71)
(0·63–1·09)
(1·04–1·18)
(1·31–1·69)
(1·54–2·23)
(1·78–2·99)
(2·19–4·69)
(0·60–1·13)
(1·05–1·20)
(1·35–1·86)
(1·61–2·65)
(1·90–3·83)
(2·40–6·71)
(0·82–1·58)
(1·01–1·17)
(1·50–2·03)
(2·14–3·29)
(3·03–5·46)
(5·02–11·76)
(0·79–1·06)
(1·01–1·07)
(1·06–1·24)
(1·08–1·39)
(1·10–1·57)
(1·12–1·90)
(0·63–1·62)
(0·96–1·18)
(1·15–1·76)
(1·34–2·48)
(1·53–3·58)
(1·83–6·33)
31 542
HR
 0·87
 1·06
 1·19
 1·29
 1·40
 1·58
 0·91
 1·04
 1·16
 1·25
 1·35
 1·52
 0·94
 1·03
 1·14
 1·24
 1·35
 1·54
 0·92
 1·05
 1·23
 1·41
 1·63
 2·02
 0·99
 1·02
 1·19
 1·40
 1·66
 2·14
 0·96
 1·03
 1·20
 1·38
 1·61
 2·02
 0·95
 1·03
 1·12
 1·22
 1·32
 1·50
 0·85
 1·08
 1·33
 1·57
 1·86
 2·41
 1·12
 0·99
 1·10
 1·29
 1·54
 1·99
 0·93
 1·06
 1·34
 1·70
 2·17
 3·14
 1·07
 0·99
 1·01
 1·07
 1·14
 1·24
 0·88
 1·07
 1·37
 1·71
 2·15
 3·04
(0·77–0·98)
(1·02–1·09)
(1·11–1·27)
(1·18–1·41)
(1·23–1·59)
(1·30–1·92)
(0·74–1·11)
(0·98–1·11)
(1·03–1·30)
(1·07–1·47)
(1·07–1·70)
(1·07–2·18)
(0·84–1·06)
(1·00–1·07)
(1·06–1·21)
(1·13–1·35)
(1·19–1·54)
(1·26–1·89)
(0·75–1·11)
(0·99–1·11)
(1·10–1·37)
(1·22–1·63)
(1·32–2·00)
(1·47–2·77)
(0·89–1·11)
(0·99–1·06)
(1·12–1·27)
(1·29–1·52)
(1·47–1·86)
(1·78–2·56)
(0·75–1·21)
(0·97–1·10)
(1·05–1·37)
(1·16–1·65)
(1·25–2·07)
(1·37–2·96)
(0·84–1·07)
(0·99–1·06)
(1·05–1·20)
(1·11–1·34)
(1·15–1·52)
(1·21–1·86)
(0·70–1·02)
(1·02–1·14)
(1·20–1·47)
(1·38–1·79)
(1·56–2·23)
(1·84–3·17)
(0·69–1·83)
(0·86–1·15)
(0·83–1·46)
(0·88–1·90)
(0·88–2·68)
(0·85–4·70)
(0·69–1·25)
(0·97–1·15)
(1·13–1·59)
(1·38–2·09)
(1·64–2·87)
(2·06–4·77)
(0·96–1·20)
(0·95–1·02)
(0·95–1·08)
(0·97–1·18)
(0·98–1·31)
(0·99–1·56)
(0·70–1·11)
(1·00–1·15)
(1·20–1·56)
(1·46–2·00)
(1·74–2·66)
(2·21–4·19)
31 542
HR
 0·78
 1·09
 1·23
 1·32
 1·40
 1·55
 1·02
 0·99
 0·94
 0·90
 0·87
 0·82
 0·85
 1·06
 1·16
 1·22
 1·29
 1·40
 1·09
 0·98
 0·98
 1·00
 1·01
 1·04
 0·90
 1·05
 1·18
 1·28
 1·39
 1·58
 1·14
 0·96
 0·92
 0·90
 0·88
 0·86
 0·92
 1·04
 1·15
 1·24
 1·33
 1·49
 0·93
 1·03
 1·13
 1·22
 1·30
 1·44
 0·29
 1·26
 1·08
 0·75
 0·51
 0·29
 0·87
 1·08
 1·32
 1·55
 1·81
 2·30
 1·05
 1·01
 1·11
 1·23
 1·35
 1·56
 0·66
 1·18
 1·68
 2·14
 2·72
 3·89
(0·57–1·06)
(1·01–1·17)
(1·05–1·45)
(1·02–1·70)
(0·97–2·03)
(0·89–2·68)
(0·66–1·58)
(0·89–1·09)
(0·71–1·23)
(0·56–1·44)
(0·44–1·71)
(0·30–2·25)
(0·68–1·07)
(1·00–1·12)
(1·03–1·31)
(1·00–1·49)
(0·97–1·72)
(0·92–2·14)
(0·86–1·38)
(0·93–1·04)
(0·85–1·14)
(0·77–1·28)
(0·70–1·46)
(0·60–1·79)
(0·79–1·03)
(1·02–1·08)
(1·10–1·26)
(1·14–1·44)
(1·18–1·64)
(1·24–2·02)
(0·63–2·06)
(0·84–1·11)
(0·63–1·34)
(0·47–1·73)
(0·34–2·29)
(0·21–3·54)
(0·77–1·10)
(1·00–1·08)
(1·04–1·27)
(1·06–1·45)
(1·06–1·68)
(1·06–2·10)
(0·73–1·20)
(0·98–1·10)
(0·99–1·30)
(0·98–1·51)
(0·95–1·79)
(0·90–2·31)
(0·04–2·02)
(0·79–2·01)
(0·43–2·69)
(0·18–3·17)
(0·06–4·20)
(0·01–6·84)
(0·55–1·36)
(0·97–1·20)
(1·06–1·65)
(1·11–2·16)
(1·13–2·91)
(1·14–4·63)
(0·84–1·31)
(0·97–1·05)
(0·98–1·27)
(0·99–1·51)
(1·00–1·83)
(1·00–2·44)
(0·40–1·08)
(1·04–1·33)
(1·35–2·09)
(1·60–2·85)
(1·84–4·01)
(2·22–6·83)
31 542
HR
(n=5688)
(n=1717)
(n=5316)
(n=1940)
(n=5798)
(n=1261)
(n=4874)
(n=2452)
(n=254)
(n=879)
(n=4697)
(n=1567)
(n=712)
(n=276)
(n=1227)
(n=860)
(n=3394)
(n=140)
(n=1799)
(n=940)
(n=43)
(n=326)
(n=1022)
(n=384)
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eligible for inclusion), the primary analysis cohort 
included 1 258 006 patients (732 657 [58%] of whom were 
women) who had 83 098 ﬁ rst cardiovascular events 
during a median follow-up of 5·2 years (IQR 2·1–9·4). 
In participants with recorded baseline blood pressure, 
188 701 (15%) had data missing for smoking status, 
691 903 (55%) for BMI, and 1 006 405 (80%) for total 
cholesterol. A third (431 663) of the cohort had blood 
pressure of 140/90 mm Hg or higher and a ﬁ fth (265 473) 
received blood pressure-lowering drugs at baseline 
(median 8 [IQR 2–13] monthly packs per year). 
Hypertension was recorded in 545 816 (43%) of the 
patients, 1 094 465 (87%) of whom were classiﬁ ed as 
having hypertension on the basis of blood pressure of 
140/90 mm Hg or higher or physician-coded diagnosis, 
and the remaining 163 541 (13%) on the basis of 
medication use only. We noted large variations across 
diﬀ erent primary care practices in terms of the patients’ 
ethnic backgrounds, socioeconomic status, and uptake 
of statins and blood pressure-lowering treatments 
(appendix p 10).
We report associations for 20/10 mm Hg changes in 
systolic/diastolic blood pressure throughout our analysis, 
but we note that the equivalence of these increments 
with respect to cardiovascular disease risks varied with 
age (overall, a 20 mm Hg change in systolic blood 
pressure was equivalent in risk to roughly 11 mm Hg 
increments in diastolic blood pressure). Systolic and 
diastolic blood pressure showed heterogeneous 
associations with diﬀ erent cardiovascular outcomes 
(ﬁ gure 1). A 20 mm Hg rise in systolic blood pressure 
showed substantially stronger associations with stable 
angina (HR 1·41 [95% CI 1·36–1·46]), subarachnoid 
haemorrhage (1·43 [1·25–1·63]), and intracerebral 
haemorrhage  (1·44 [1·32–1·58]) than with total 
cardiovascular disease (1·26 [1·25–1·28]). Compared 
with systolic blood pressure, diastolic blood pressure 
showed substantially weaker associations with stable 
angina, peripheral arterial disease, and myocardial 
infarction and with total cardiovascular disease (ﬁ gure 1). 
Abdominal aortic aneurysm had the strongest association 
of all cardiovascular diseases with diastolic blood 
pressure (HR 1·45 [95% CI 1·34–1·56]) and mean arterial 
pressure (HR per 10 mm Hg 1·61 [1·48–1·75]), the 
weakest association with systolic blood pressure 
(1·08 [1·00–1·17] per 20 mm Hg), and was the only 
outcome for which the association with higher pulse 
pressure was reversed (HR per 10 mm Hg 0·91 
[0·86–0·98]) (appendix p 11). Conversely, we noted that 
peripheral arterial disease had an inverse association 
with mean arterial pressure (HR 0·90 [95% CI 0·86–0·94]) 
and the strongest association of all cardiovascular 
diseases with pulse pressure (1·23 [1·20–1·27]). 
Associations with mid-blood pressure were strongest for 
stroke (ischaemic stroke, subarachnoid haemorrhage, 
and intracerebral haemorrhage), but very similar across 
other cardiovascular outcomes (appendix p 11).
Myocardial infarction had a stronger association with 
systolic blood pressure in women than in men (p<0·0001), 
but associations with other outcomes were similar in both 
sexes (appendix p 12). Associations with blood pressure 
decreased very little after adjustment for cardiovascular 
disease risk factors, with the largest attenuation in HRs 
noted for heart failure upon adjustment for BMI 
(appendix p 13). Further adjustment for blood pressure-
lowering drugs attenuated the associations of systolic and 
diastolic blood pressure with all endpoints by 20–30%, but 
had no eﬀ ect on the associations with stroke outcomes 
(appendix p 13). Similarly, the age-adjusted and sex-
adjusted associations with blood pressure were 
substantially weaker in people who received blood 
pressure-lowering treatments at baseline than in those 
who did not, except for the associations with ischaemic 
stroke and intracerebral haemorrhage, which were similar 
between treated and untreated patients, and the 
associations with subarachnoid haemorrhage, which were 
larger (especially with diastolic blood pressure) in treated 
than in untreated patients (appendix pp 14–15).
Associations with both systolic and diastolic blood 
pressure decreased with age for all outcomes at varying 
rates for diﬀ erent outcomes (ﬁ gure 2). Across diﬀ erent 
diseases and ages, the shape of associations with systolic 
blood pressure (ﬁ gure 3) and diastolic blood pressure 
(ﬁ gure 4) also showed substantial variation. We did not 
record J-shaped associations with any of the outcomes. 
Between 30 and 79 years of age, the associations of systolic 
and diastolic blood pressure with stable and unstable 
angina, myocardial infarction, unheralded  coronary 
death, and subarachnoid haemorrhage were generally 
linear, whereas associations with other outcomes were 
mostly log-linear. For the linear associations, the risk was 
lowest in people with systolic blood pressure 
90–114 mm Hg and was signiﬁ cantly lower than for a 
higher systolic blood pressure of 115–129 mm Hg). For the 
log-linear associations, there was little or no further 
reduction in risk for blood pressure below about 
130/85 mm Hg, whereas modest increases in either 
systolic or diastolic blood pressure above this range were 
accompanied by large increases in hazard ratios, especially 
for unheralded coronary death, heart failure, ischaemic 
stroke, intracerebral haemorrhage, and peripheral arterial 
disease. In people aged 60 years and older, systolic blood 
pressure was no longer associated with subarachnoid 
haemorrhage or with abdominal aortic aneurysm 
(ﬁ gure 3). In those aged 80 years and older, the strongest 
associations for systolic blood pressure were with stable 
angina, myocardial infarction, intracerebral haemorrhage, 
Figure 4: Forest plot of HRs (95% CIs) for diﬀ erent cutoﬀ s of diastolic blood 
pressure (vs reference 75 mm Hg) adjusted for age and sex
Blood pressure was modelled as a continuous variable with splines with three 
knots. Adjustments include age, quadratic age, and stratiﬁ cation by sex and 
primary care practice. CIs are Bonferroni corrected (3 age groups × 6 
categories × 12 endpoints=216 tests). HR=hazard ratio.
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and peripheral arterial disease (all linear), and we noted a 
weak U-shaped association for unheralded coronary death 
(with systolic blood pressure 140–159 mm Hg having the 
lowest risk), whereas associations with the remaining 
outcomes were either not signiﬁ cant or were recorded 
only with high blood pressure (≥140/90 mm Hg) (ﬁ gure 3). 
Similar patterns were recorded in men and women 
(appendix pp 16–19), and in patients treated or not treated 
with blood pressure-lowering drugs at baseline 
(appendix pp 20–23).
The lifetime risk of total cardiovascular disease at 
30 years of age was 63·3% (95% CI 62·9–63·8) in 
people with hypertension and 46·1% (45·5–46·8) in 
those with healthy blood pressure (absolute diﬀ erence 
17·2% [95% CI 13·9–20·5]) (ﬁ gure 5, and see 
appendix p 24 for estimates by sex). Stable and unstable 
angina were the most frequent outcomes, with lifetime 
risks of around 10% in people with hypertension and 
6% in those with normal blood pressure. Lifetime risks 
in people with hypertension were also high for 
myocardial infarction (8·0% [7·8–8·3]), heart failure 
(7·8% [7·6–8·1]), and ischaemic stroke(7·6% [7·3–7·8]) 
(ﬁ gure 5). However, these risks did not increase by the 
same proportion in people with hypertension compared 
with those without the disorder. Thus, ischaemic stroke, 
transient ischaemic attack, and abdominal aortic 
aneurysm were only 1·1-times more common in 
patients with hypertension than in those with normal 
blood pressure, whereas heart failure was 1·5-times 
more common and stable angina 1·8-times more 
common (see appendix p 7 for lifetime risks, risk 
diﬀ erences, and lifetime risk ratios for all outcomes and 
for other index ages).
The mean number of cardiovascular disease-free life-
years lost associated with hypertension was 5·0 years 
(95% CI 4·8–5·4) from 30 years of age, 3·4 years 
(3·3–3·6) from 60 years, and 1·6 years (1·5–1·7) from 
80 years (ﬁ gure 6; appendix p 25 shows estimates by sex). 
The largest proportions of cardiovascular disease-free 
years of life lost associated with hypertension at index 
age 30 years were attributable to stable angina (22%), 
unstable angina (21%), and myocardial infarction (15%). 
However, from index age 80 years, stable angina and 
heart failure accounted for most (19% each) of all 
cardiovascular disease-free years of life lost, followed by 
unstable angina (15%), myocardial infarction (12%), and 
Figure 5: Lifetime risk (95% CI) of 12 diﬀ erent cardiovascular diseases in people with hypertension or normal BP from index age 30 years
Hypertension was deﬁ ned as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg or use of BP-lowering treatments or physician-recorded diagnosis at baseline. BP=blood pressure.
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ischaemic stroke (10%; ﬁ gure 6). Isolated systolic 
hypertension (prevalent in 35% [109 587/314 574], 60% 
[113 625/190 300, and 64% [26 274/40 942] of patients with 
hypertension aged 30–59, 60–79, and ≥80 years, 
respectively) accounted for a quarter of the cardiovascular 
disease-free years of life lost associated with hypertension 
in those aged 30–59 years, and nearly half at older ages. 
By contrast, isolated diastolic hypertension (prevalent in 
10% [31 404/314 574], 1·4% [2761/190 300], and 0·6% 
[259/40 942] of patients with hypertension aged 30–59, 
60–79, and ≥80 years, respectively) accounted for only 
0·5% of years of life lost to cardiovascular disease 
associated with hypertension in those aged 30–59 years, 
with a negligible contribution (<0·01%) in older age 
groups (appendix p 7).
Our sensitivity analyses showed that general practice 
variability had no eﬀ ect on the overall associations, since 
random eﬀ ects meta-analysis estimates were almost 
identical to the ﬁ xed eﬀ ects estimates reported in our 
main analysis (appendix p 26). The age-adjusted and sex-
adjusted associations between blood pressure and 
endpoints restricted to hospital admissions and death 
were comparable to the main analysis but were stronger 
between systolic blood pressure and peripheral arterial 
disease and between diastolic blood pressure and 
abdominal aortic aneurysm, and weaker between systolic 
blood pressure and stable angina (appendix p 27). 
Patients who had more than one blood pressure 
measurement (60% of the cohort) had similar 
associations with endpoints as those based on a single 
measurement, with the exception of stronger associations 
with peripheral arterial disease and stable angina 
(appendix p 28). Similarly, the use of a single 
measurement closest to the baseline instead of the 
Figure 6: Years of life lost to cardiovascular disease up to 95 years of age associated with hypertension at index ages 30, 60, and 80 years, adjusted for sex, smoking, diabetes, and total and 
high-density lipoprotein cholesterol
83 098 total cardiovascular disease events occurred.
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average blood pressure resulted in smaller but similarly 
patterned associations (appendix p 29). Associations 
between blood pressure and cardiovascular outcomes 
when missing baseline blood pressure was imputed 
closely matched the main analysis estimates based on 
complete cases (appendix p 30). The age-adjusted 
mortality rate was very similar between people with and 
without baseline blood pressure measurements (HR for 
mortality in people with missing vs recorded blood 
pressure 1·01 [95% CI 0·99–1·02]).
Discussion
In this study of 1·25 million patients accruing 
83 098  cardiovascular events of 12 diﬀ erent diseases 
during 5·2 years median follow-up, we showed that the 
lifetime burden of hypertension remains substantial, 
despite modern therapy. We show that across diﬀ erent 
diseases and diﬀ erent ages there was substantial 
heterogeneity in associations with blood pressure, not 
only in terms of strength but also in whether an 
association existed and how it was shaped.
An important advance of this study over previous 
reports was our ability to compare in one study the 
associations of blood pressure across a substantially wider 
range of incident cardiovascular diseases,2,4 across a 
broader age range (including people younger than 
40 years), and a wider range of blood pressure values 
(including <115/75 mm Hg). This higher resolution 
approach was enabled by electronic health record linkage 
and is generalisable to the population rather than those 
selected individuals who participate in trials or 
observational research (99% of the UK population are 
registered with a primary care practice16), and is clinically 
relevant, focusing on measurements as recorded in 
clinical care.
For nearly all cardiovascular diseases, we noted that the 
relative risks decreased with age and no signiﬁ cant 
deviations from linearity occurred in the associations of 
either systolic or diastolic blood pressure with diﬀ erent 
outcomes at any age. The absence of J-shape associations 
is consistent with previous studies, including the 
Prospective Studies Collaboration2 and the Framingham 
study (in which J-shape associations with diastolic blood 
pressure occurred only when accompanied by systolic 
blood pressure >140 mm Hg),17 and is supported by trial 
evidence in elderly people that shows signiﬁ cant and 
sustained risk reduction for cardiovascular endpoints 
with lowering of blood pressure.18
Our study reports the lifetime risks of speciﬁ c 
cardiovascular outcomes as the ﬁ rst presentation of 
cardiovascular disease (panel). Unlike previous studies of 
lifetime risks, we excluded people who had experienced 
diﬀ erent types of cardiovascular disease before the 
outcome of interest and therefore our estimates are 
expected to be substantially lower, especially for outcomes 
associated strongly with age or pre-existing cardiovascular 
disease, than those in previous studies. The lifetime risk 
of heart failure in the Framingham study was 20% overall, 
and between 11 and 17% (depending on sex) when people 
with previous myocardial infarction were excluded.19 In 
our study, we show that the lifetime risk of heart failure 
after accounting (by competing risks modelling) for 
patients who experienced another cardiovascular outcome 
before heart failure is 5%, and is almost twice as high in 
people with hypertension as in those with normal blood 
pressure. Similarly, our estimated lifetime risk for stroke 
(for which we combined ischaemic and haemorrhagic 
stroke for comparability) was 8–10%, which is 
substantially lower than the 17–20% reported in the 
Framingham study.21 This diﬀ erence could be explained 
by the late manifestation of ischaemic strokes and 
because a substantial proportion of them were preceded 
by a transient ischaemic attack event. Conversely, for 
subarachnoid haemorrhage, which is more prevalent in 
younger ages, our lifetime risk estimates (0·6–0·9%) 
were similar to the previously reported estimates of 
around 0·5%.22 For composite cardiovascular disease 
outcomes, our approach is equivalent to other studies, 
leading to broadly similar estimates allowing for 
diﬀ erences in risk factor prevalence, composition of 
endpoints, and diﬀ erent index ages.3,23,24
Our ﬁ ndings are also consistent with the pattern of 
initial cardiovascular disease presentations associated 
with hypertension reported in 2694 Framingham 
participants recruited in the 1970s, which to our 
knowledge is the only previous analysis of cardiovascular 
disease risks (up to 12 years) with some disaggregation 
into diﬀ erent outcomes under a competing risks 
framework.5 Consistent with our ﬁ ndings, the type of 
cardiovascular outcome in this Framingham subcohort 
varied by age (with stroke being more common in older 
hypertensive patients), and sex (with myocardial 
infarction or fatal coronary heart disease being more 
frequent in men with hypertension, and stroke more 
common in women with hypertension).
Substantial debate has surrounded the beneﬁ ts of 
treating mild (stage 1) hypertension in young people, 
especially in those without evidence of target organ 
damage or calculated to have a low 10-year risk of 
cardiovascular disease.25 A recent meta-analysis26 showed 
that during a 5-year follow-up, no signiﬁ cant reduction in 
cardiovascular events resulted from the administration of 
blood pressure-lowering treatments to people with mild 
hypertension, but longer time horizons might be needed 
to show the beneﬁ ts of long-term primary prevention in 
such populations. In the absence of long-term randomised 
trials, our estimates of lifetime risk and cardiovascular 
disease-free years of life lost provide epidemiological 
evidence of substantial morbidity associated with raised 
blood pressure, irrespective of the starting baseline risk.
Isolated systolic and combined systolic and diastolic 
hypertension accounted for the largest proportion of 
cardiovascular disease-free years of life lost, with a 
negligible contribution from isolated diastolic 
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hypertension, even in those aged 30–59 years in whom 
the prevalence of isolated diastolic hypertension was 
highest. Thus, our estimates support the shift in 
guideline focus in recent years from the importance of 
diastolic towards the greater importance of systolic 
pressure in people aged 60 years and older.27
Our data support the possibility that blood pressure 
functions through diﬀ erent underlying biological 
mechanisms for diﬀ erent diseases. For example, the 
strong associations of blood pressure with stable angina 
and intracerebral haemorrhage might represent the 
respective causative contributions of left ventricular 
hypertrophy and vascular rupture to these disorders. 
Similarly, the arterial rigidity that protects against 
abdominal aortic aneurysm might account for the weak 
association with systolic blood pressure and for the 
stronger association with diastolic blood pressure and 
mean arterial pressure—ﬁ ndings consistent with 
previous, smaller, studies of risk factors for abdominal 
aortic aneurysm.28,29
Our ﬁ ndings have important clinical implications. 
Recently published clinical practice guidelines from the 
USA30 and the UK31 agree that the primary purpose of 
assessment of cardiovascular risk is to provide the basis of 
a risk discussion with the patient. Our estimates of 
lifetime risks and years of cardiovascular disease-free life 
lost to diﬀ erent diseases can be used to extend the existing 
counselling of patients and decision making, which is 
based on heart attack and stroke risks alone. Here, we 
show the importance of other diseases that might be more 
common; of the 5 years of cardiovascular disease-free life 
lost associated with hypertension, nearly half were 
attributable to stable and unstable angina, whereas in the 
80 years and older age group, heart failure accounted for 
nearly a ﬁ fth of the years of life lost. Diﬀ erent diseases 
might also aﬀ ect patient quality of life diﬀ erently—for 
example, patients might value living free from heart 
failure or peripheral arterial disease diﬀ erently to living 
free from a heart attack or stroke. Despite the high burden 
of heart failure, angina, and peripheral arterial disease in 
this population, very few large-scale studies have focused 
on risk factor associations with these outcomes in 
previously cardiovascular disease-free patients.19,32–34
Our estimates also emphasise the unmet need of 
existing blood pressure-lowering strategies, as shown by 
the width of the separation of the lifetime risk curves in 
people with and without hypertension. Better mitigation 
of these excess risks could come from better 
implementation of existing blood pressure-lowering 
treatments and through better management of other 
cardiovascular risk factors as part of global risk estimation. 
An important need also exists for new interventions and 
our ﬁ ndings have implications for the design of new, and 
the interpretation of existing, clinical trials. For example, 
we show that heart failure and peripheral arterial disease 
are among the most common initial presentations of 
cardiovascular disease, but are included less frequently in 
the primary outcome of blood pressure-lowering trials.35 
The beneﬁ ts of treatment of hypertension to reduce the 
risk of myocardial infarction and stroke are well 
established36 and although our study has shown less 
pronounced associations of hypertension with other 
manifestations of cardiovascular disease, the need for 
vigorous treatment as part of a package of risk-reduction 
measures remains undiminished.
Although a major strength of this study is the ability to 
resolve a wide range of cardiovascular diseases in a 
Panel: Research in context
Systematic review
We searched Medline for original research from the past 10 years describing the 
age-speciﬁ c associations of blood pressure variables in large observational studies with the 
initial presentation of a wide range of cardiovascular diseases (in which three or more 
diseases were studied simultaneously). We used the search terms ”ﬁ rst [incident] 
cardiovascular”, ”age-speciﬁ c”, “blood pressure associations”, “competing risks and 
hypertension”, “years of life-lost and hypertension”, and “lifetime risks and hypertension” 
and widened our search for “hypertension” and diﬀ erent causes of death, and used various 
(three or more) combinations of each endpoint studied as keywords in the same search. 
We did not restrict our search dates but we only searched for studies published in English. 
We screened publications by abstract for relevance. The only observational study that 
fulﬁ lled the criteria for inclusion of several cardiovascular endpoints was the Prospective 
Studies Collaboration2 which reported the age-speciﬁ c associations (age 40–89 years, 
participant recruitment period 1950–90) of blood pressure with death from diﬀ erent types 
of stroke and coronary heart disease, and the overall (all ages) associations of blood 
pressure with a wider range of cardiovascular outcomes. One study fulﬁ lled the criteria for 
analysis of time to ﬁ rst cardiovascular event type in people with hypertension under a 
competing risks framework.5 Various analyses of the Framingham cohort reported on the 
associations of blood pressure with incident cardiovascular diseases beyond heart attack 
and stroke (eg, heart failure19 and peripheral arterial disease20), but hazard ratios were not 
directly comparable because they were based on diﬀ erent subsets of the Framingham 
cohort or oﬀ spring. Most other studies identiﬁ ed in our searches were small (often 
<1000 participants) or not relevant because they focused on the associations of blood 
pressure with cardiovascular disease risk in people who had already developed the diﬀ erent 
cardiovascular diseases studied here.
Interpretation
Our study conﬁ rms the ﬁ ndings from several smaller studies (meta-analysed in the 
Prospective Studies Collaboration) that investigated individual cardiovascular diseases. 
Our results extend the previous associations of blood pressure to a wider range (12) of 
cardiovascular diseases, some of which have rarely been studied as initial presentations, 
and include non-fatal and chronic presentations of cardiovascular disease (heart failure, 
peripheral arterial disease, and stable angina); to younger age groups (<40 years); to 
people with lower blood pressure (<115/75 mm Hg); and to the contemporary population 
in whom the use of blood pressure-lowering medications is widespread (such drugs were 
rarely used in the participants of the Prospective Studies Collaboration). Moreover, we 
report on the associations of a wide range of blood pressure measures for these 
outcomes, and show that for some cardiovascular diseases, pulse pressure and mean 
arterial pressure have prognostic value. For the ﬁ rst time, we estimate lifetime risks and 
years of life lost to diﬀ erent types of cardiovascular disease through the application of 
competing risks methodology. A better understanding of the diﬀ erent associations of 
blood pressure with diﬀ erent types of cardiovascular disease and the lifetime risks 
associated with hypertension at diﬀ erent ages will help to focus guidelines and clinicians 
to the disease areas in which screening and treatments are more likely to have an eﬀ ect.
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validated electronic hospital record linkage setting,7 
limitations do exist in the amount of clinical detail 
presently recorded in national electronic hospital records, 
such as on imaging results. Our lifetime risks were 
estimated based on extrapolation of event rates recorded 
in people entering the cohort at diﬀ erent ages, rather 
than following up each patient over their residual 
lifetime. Although we account for age at measurement 
(by including age as a factor in the model and in the 
baseline hazard), we have not accounted for changes in 
blood pressure and other risk factors over time. A more 
detailed analysis of lifetime risks would take repeated 
measures into consideration to account for potential 
changes and would adjust for the time-dependent eﬀ ect 
of medications taken long term.
In conclusion, systolic and diastolic blood pressure 
show heterogeneous associations across a wide range of 
acute and chronic cardiovascular diseases and at diﬀ erent 
ages. These ﬁ ndings have implications for the design of 
new trials and preventive strategies to address the 
substantial contemporary unmitigated lifetime burden 
of hypertension.
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